Update launch ChondroCelect (Tigenix) and status of reimbursement applications http://tiny.cc/FRRhS
posted 14 hours ago
FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.
Website: http://www.glpg.com
Email:
Phone: +32 15 34 29 00
Flandersbio Member
More address details
Galapagos operates a hybrid business model, combining internal R&D programs with target and drug discovery service activities.
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with four clinical and over 40 small molecule discovery/pre-clinical programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, Merck & Co. and Roche, Galapagos is eligible to receive up to €3 billion in downstream milestones, plus royalties. Together with the service operations of BioFocus and Argenta, Galapagos now has more than 640 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium.
Galapagos has discovered new drug targets (human proteins that are starting points for the development of novel drugs) using human primary cells relevant for rheumatoid arthritis, osteoarthritis and osteoporosis. Galapagos applies these targets to find small molecules that change the activity of these proteins and thereby can influence the course of the disease.
The molecules then form the basis for the development of first-in-class medicines against these bone and joint diseases. This approach is expected to yield a breakthrough in treatment by stopping the disease rather than just treating the symptoms. Pre-clinical development has started on the first rheumatoid arthritis candidate compound, with the aim to initiate a clinical Phase I trial in early 2009.
BioFocus DPI, Galapagos' services division, meets the pharma industry’s need for drug discovery tools and expertise by providing a full range of drug discovery services, from target discovery through to delivery of pre-clinical candidates. The main business areas of BioFocus DPI include informatics; biology (target discovery and screening), compound libraries, medicinal chemistry and ADMET services. BioFocus DPI currently serves more than 30 large pharmaceutical companies and biotechnology companies in Europe, North America, and Japan. With its operations in the UK, The Netherlands, Switzerland, the USA and a sales office in Japan, BioFocus DPI is well positioned to support this client base.
Galapagos has entered into several long term alliances with top ten pharma companies: Galapagos' rheumatoid arthritis program is partnered with Janssen Pharmaceutica, the arthritis program with GSK and the osteoporosis program with Eli Lilly. Additionally, Galapagos has established strategic alliances in anti-infectives with GlaxoSmithKline, metabolic and inflammatory diseases with Merck & Co, Inc. and in COPD with Roche.
Through its alliance strategy, Galapagos is eligible to receive in excess of €3 billion in success-dependent downstream milestone revenues plus up to double-digit royalties on commercial products. Galapagos is progressing over 40 target-based programs in R&D, the majority of which are part of the alliances.
Address:
Generaal De Wittelaan L11/A3
2800
Mechelen
Belgium
Route: Via Google Maps
Website: http://www.glpg.com
Phone: +32 15 34 29 00
Fax: +32 15 34 29 01
Foundation date: 1/1999
Email:
Sorry, to find this company's location on Google Maps, Javascript is required.